Abstract:BackgroundPortal hypertension is a key complication of portal hypertension, which is responsible for the development of varices, ascites, bleeding, and hepatic encephalopathy, which, in turn, cause a high mortality and requirement for liver transplantation.AimThis review deals with the present day state-of-the-art preventative treatments of portal hypertension in cirrhosis according to disease stage. Two main disease stages are considered, compensated and decompensated cirrhosis, the first having good prognosis and being mostly asymptomatic, and the second being heralded by the appearance of bleeding or non-bleeding complications of portal hypertension.ResultsThe aim of treatment in compensated cirrhosis is preventing clinical decompensation, the more frequent event being ascites, followed by variceal bleeding and hepatic encephalopathy. Complications are mainly driven by an increase of hepatic vein pressure gradient (HVPG) to values ≥10 mmHg (defining the presence of Clinically Significant Portal Hypertension, CSPH). Before CSPH, the treatment is limited to etiologic treatment of cirrhosis and healthy life style (abstain from alcohol, avoid/correct obesity…). When CSPH is present, association of a non-selective beta-blocker (NSBB), including carvedilol should be considered. NSBBs are mandatory if moderate/large varices are present. Patients should also enter a screening program for hepatocellular carcinoma. In decompensated patients, the goal is to prevent further bleeding if the only manifestation of decompensation was a bleeding episode, but to prevent liver transplantation and death in the common scenario where patients have manifested first non-bleeding complications. Treatment is based on the same principles (healthy life style..) associated with administration of NSBBs in combination if possible with endoscopic band ligation if there has been variceal bleeding, and complemented with simvastatin administration (20-40 mg per day in Child–Pugh A/B, 10–20 mg in Child C). Recurrence shall be treated with TIPS. TIPS might be indicated earlier in patients with: 1) Difficult/refractory ascites, who are not the best candidates for NSBBs, 2) patients having bleed under NSBBs or showing no HVPG response (decrease in HVPG of at least 20% of baseline or to values equal or below 12 mmHg). Decompensated patients shall all be considered as potential candidates for liver transplantation.ConclusionTreatment of portal hypertension has markedly improved in recent years. The present day therapy is based on accurate risk stratification according to disease stage.

Esophageal and Gastric Variceal Bleeding in Liver Cirrhosis: Embolization or Shunt

Should Vasoconstrictors Be Considered in a Cirrhotic Patient with Acute Non-variceal Upper Gastrointestinal Bleeding?

Surgical shunts compared with endoscopic sclerotherapy for the treatment of variceal bleeding in adults with portal hypertension: a systematic review and meta-analysis.

Prevention and treatment of gastroesophageal variceal bleeding in patients with liver cirrhosis

Progress in Endoscopic and Interventional Treatment of Esophagogastric Variceal Bleeding

Clinical Application of Gastroesophageal Varices Embolization Combined with Partial Splenic Embolization in Portal Hypertension

Surgical therapy procedure in cirrhosis with portal hypertension

Portal Vein Thrombosis Can Aggravate Esophageal Variceal Bleeding After Endoscopic Variceal Ligation

Role of portosystemic shunt in the treatment of portal hypertension with liver cirrhosis

The portal hypertension syndrome: etiology, classification, relevance, and animal models

Medical management of variceal hemorrhage

Percutaneous Transhepatic Variceal Embolization Combined with Partial Splenic Embolization for Treatment of Esophagogastric Variceal Bleeding in Patients with Liver Cirrhosis

Two Surgical Procedures for Esophagogastric Variceal Bleeding in Patients with Portal Hypertension

Management of Liver Decompensation in Advanced Chronic Liver Disease: Ascites, Hyponatremia, and Gastroesophageal Variceal Bleeding

Endoscopic band ligation versus pharmacological therapy for variceal bleeding in cirrhosis: a meta-analysis.

Clinical value of regular endoscopic treatment for esophageal and gastric variceal bleeding in patients with liver cirrhosis

Endoscopic Features and Classification of Gastric Varices in Patients with Portal Hypertension

[Advances in Basic and Clinical Research on Liver Cirrhosis in 2016].

Prevention and Treatment of Portal Hypertension Complicated with Hemorrhage in Patients with Liver Cirrhosis through New Knowledge on its Pathogenesis

Effects of Modified Splenocaval Shunt Plus Devascularization on Esophagogastric Variceal Bleeding: a Comparative Study of This Treatment and Devascularization Only in Cirrhotic Portal Hypertension

Prevention for Rebleeding of Esophageal Varices under the Guidance of Hepatic Venous Pressure Gradient